Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Equity Income (2019 - 2025)

Historic Equity Income for Ascendis Pharma A (ASND) over the last 7 years, with Q4 2025 value amounting to $1.5 million.

  • Ascendis Pharma A's Equity Income rose 13162.3% to $1.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $16.1 million, marking a year-over-year increase of 27651.73%. This contributed to the annual value of $18.4 million for FY2025, which is 18597.54% up from last year.
  • According to the latest figures from Q4 2025, Ascendis Pharma A's Equity Income is $1.5 million, which was up 13162.3% from -$8.8 million recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Equity Income registered a high of $36.0 million during Q4 2021, and its lowest value of -$8.8 million during Q3 2025.
  • For the 5-year period, Ascendis Pharma A's Equity Income averaged around $1.9 million, with its median value being -$4.1 million (2021).
  • As far as peak fluctuations go, Ascendis Pharma A's Equity Income skyrocketed by 212709.27% in 2021, and later crashed by 55211.81% in 2023.
  • Over the past 5 years, Ascendis Pharma A's Equity Income (Quarter) stood at $36.0 million in 2021, then crashed by 122.56% to -$8.1 million in 2022, then surged by 61.27% to -$3.1 million in 2023, then crashed by 55.4% to -$4.9 million in 2024, then surged by 131.62% to $1.5 million in 2025.
  • Its Equity Income was $1.5 million in Q4 2025, compared to -$8.8 million in Q3 2025 and -$4.6 million in Q2 2025.